Markers of vascular differentiation, proliferation and tissue remodeling in juvenile nasopharyngeal angiofibromas

Experimental and Therapeutic Medicine

Volumn 1, Issue 6, 2010, Pages 921-926

  Nonogaki, Suely ^a   Campos, Heloisa G A ^b   Butugan, Ossamu ^c   Soares, Fernando A ^b   Mangone, Flávia Regina Rotea ^c   Torloni, Humberto ^b   Mitzi Brentani, M ^c  

^a INSTITUTO ADOLFO LUTZ   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Endoglin; Friend leukemia integration 1; GLUT 1; Juvenile nasopharingeal angiofibroma; Podoplanin; Secreted acid protein rich in cysteine; Stromelysin 3; Vascular endothelial growth factor receptor 3

Indexed keywords

BIOLOGICAL MARKER; ENDOGLIN; GLUCOSE TRANSPORTER 1; PODOPLANIN; PROTEIN; PROTEIN SPARC; STROMELYSIN 3; TRANSCRIPTION FACTOR FLI 1; UNCLASSIFIED DRUG; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; HEMANGIOFIBROMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NASOPHARYNX TUMOR; PROTEIN DETERMINATION; SCHOOL CHILD; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 78049317720     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2010.141     Document Type: Article

References (42)

1. Coutinho-Camillo CM, Brentani MM and Nagai MA: Genetic alterations in juvenile nasopharyngeal angiofibromas. Head Neck 30: 390-400, 2008.
2. Beham A, Beham-Schmid C, Regauer S, et al: Nasopharyngeal angiofibroma: true neoplasm or vascular malformation? Adv Anat Pathol 7: 36-46, 2000.
3. Schick B and Urbschat S: New aspects of pathogenesis of juvenile angiofibroma. Hosp Med 65: 269-273, 2004.
4. Eivazi B, Ardelean M, Bäumler W, et al: Update on hemangiomas and vascular malformations of the head and neck. Eur Arch Otorhinolaryngol 266: 187-197, 2009.
5. Starlinger V, Wendler O, Gramann M, et al: Laminin expression in juvenile angiofibroma indicates vessel's early developmental stage. Acta Otolaryngol 127: 1310-1315, 2007.
6. Gramann M, Wendler O, Haeberle L and Schick B: Prominent collagen type VI expression in juvenile angiofibromas. Histochem Cell Biol 131: 155-164, 2009.
7. Gramann M, Wendler O, Haeberle L and Schick B: Expression of collagen types I, II and III in juvenile angiofibromas. Cells Tissues Organs 189: 403-409, 2009.
8. Enjolras O, Wassef M and Chapot R: Introduction: ISSVA Classification. In: Color Atlas of Vascular Tumors and Vascular Malformations. Cambridge University Press, New York, pp3-11, 2007.
9. Tamm E, Jungkunz W, Marsch WC and Lütjen-Drecoll E: Increase in types IV and VI collagen in cherry haemangiomas. Arch Dermatol Res 284: 275-282, 1992.
10. Pusztaszeri MP, Seelentag W and Bosman FT: Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues. J Histochem Cytochem 54: 385-395, 2006.
11. Schiff M, Gonzalez AM, Ong M, et al: Juvenile nasopharyngeal angiofibroma contain an angiogenic growth factor: basic FGF. Laryngoscope 102: 940-945, 1992.
12. Dillard DG, Cohen C, Muller S, et al: Immunolocalization of activated transforming growth factor beta1 in juvenile nasopharyngeal angiofibroma. Arch Otolaryngol Head Neck Surg 126: 723-725, 2000.
13. Zhang PJ, Weber R, Liang HH, et al: Growth factors and receptors in juvenile nasopharyngeal angiofibroma and nasal polyps: an immunohistochemical study. Arch Pathol Lab Med 127: 1480-1484, 2003.
14. Brieger J, Wierzbicka M, Sokolov M, et al: Vessel density, proliferation, and immunolocalization of vascular endothelial growth factor in juvenile nasopharyngeal angiofibromas. Arch Otolaryngol Head Neck Surg 130: 727-731, 2004.
15. Saylam G, Yücel OT, Sungur A, et al: Proliferation, angiogenesis and hormonal markers in juvenile nasopharyngeal angiofibroma. Int J Pediatr Otorhinolaryngol 70: 227-234, 2006.
16. Schuon R, Brieger J, Heinrich UR, et al: Immunohistochemical analysis of growth mechanisms in juvenile nasopharyngeal angiofibroma. Eur Arch Otorhinolaryngol 264: 389-394, 2007.
17. Ponti G, Losi L, Pellacani G, et al: Wnt pathway, angiogenetic and hormonal markers in sporadic and familial adenomatous polyposis-associated juvenile nasopharyngeal angiofibromas (JNA). Appl Immunohistochem Mol Morphol 16: 173-178, 2008.
18. Montag AG, Tretiakova M and Richardson M: Steroid hormone receptor expression in nasopharyngeal angiofibromas. Consistent expression of estrogen receptor beta. Am J Clin Pathol 125: 832-837, 2006.
19. Pauli J, Gundelach R, Vanelli-Rees A, et al: Juvenile nasopharyngeal angiofibroma: an immunohistochemical characterisation of the stromal cell. Pathology 40: 396-400, 2008.
20. Nagy JA, Chang SH, Dvorak AM and Dvorak HF: Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer 100: 865-869, 2009.
21. Truong AH and Ben-David Y: The role of Fli-1 in normal cell function and malignant transformation. Oncogene 19: 6482-6489, 2000.
22. Folpe AL, Chand EM, Goldblum JR and Weiss SW: Expression of Fli-1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics. Am J Surg Pathol 25: 1061-1066, 2001.
23. Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ and Ellis LM: Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res 14: 1931-1937, 2008.
24. Breiteneder-Geleff S, Soleiman A, Kowalski H, et al: Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 154: 385-394, 1999.
25. Folpe AL, Veikkola T, Valtola R and Weiss SW: Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas. Mod Pathol 13: 180-185, 2000.
26. Harik SI, Hall AK, Richey P, et al: Ontogeny of the erythroid/HepG2-type glucose transporter (GLUT-1) in the rat nervous system. Brain Res Dev Brain Res 72: 41-49, 1993.
27. Gillies RJ, Robey I and Gatenby RA: Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 49: S24-S42, 2008.
28. North PE, Waner M, Mizeracki A, et al: GLUT-1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol 31: 11-22, 2000.
29. Aird WC: Molecular heterogeneity of tumor endothelium. Cell Tissue Res 335: 271-281, 2009.
30. Clark CJ and Sage EH: A prototypic matricellular protein in the tumor microenvironment - where there's SPARC, there's fire. J Cell Biochem 104: 721-732, 2008.
31. Rio MC: From a unique cell to metastasis is a long way to go: clues to stromelysin-3 participation. Biochimie 87: 299-306, 2005.
32. Podhajcer OL, Benedetti L, Girotti MR, Prada F, Salvatierra E and Llera AS: The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev 27: 523-537, 2008.
33. Krstulja M, Car A, Bonifacić D, Braut T and Kujundzić M: Nasopharyngeal angiofibroma with intracellular accumulation of SPARC - a hypothesis (SPARC in nasopharyngeal angiofibroma). Med Hypotheses 70: 600-604, 2008.
34. Mangone FR, Brentani MM, Nonogaki S, et al: Overexpression of Fos-related antigen-1 in head and neck squamous cell carcinoma. Int J Exp Pathol 86: 205-212, 2005.
35. Baluk P, Morikawa S, Haskell A, Mancuso M and McDonald DM: Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 163: 1801-1815, 2003.
36. Cao R, Eriksson A, Kubo H, Alitalo K, Cao Y and Thyberg J: Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ Res 94: 664-670, 2004.
37. Duerr S, Wendler O, Aigner T, Karosi S and Schick B: Metalloproteinases in juvenile angiofibroma - a collagen rich tumor. Hum Pathol 39: 259-268, 2008.
38. Motrescu ER, Blaise S, Etique N, et al: Matrix metalloproteinase-11/stromelysin-3 exhibits collagenolytic function against collagen VI under normal and malignant conditions. Oncogene 27: 6347-6355, 2008.
39. Chlenski A, Liu S, Guerrero LJ, et al: SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix. Int J Cancer 118: 310-316, 2006.
40. Kato Y, Lewalle JM, Baba Y, et al: Induction of SPARC by VEGF in human vascular endothelial cells. Biochem Biophys Res Commun 287: 422-426, 2001.
41. Sennes LU, Fortes FS, Butugan O, Saldiva PH and Bernardi FC: Tissue maturation correlating to clinical manifestations in juvenile angiofibroma. Ann Otol Rhinol Laryngol 114: 705-708, 2005.
42. Delany AM and Canalis E: The metastasis-associated metalloproteinase stromelysin-3 is induced by transforming growth factor-beta in osteoblasts and fibroblasts. Endocrinology 142: 1561-1566, 2001.